Protecting NVAF patients from stroke: appropriate dosing of DOACs
This article highlights the latest guidance on appropriate dosing of direct-acting oral anticoagulants (DOACs) in people with non-valvular atrial fibrillation (NVAF). Key considerations include specific dose adjustment requirements for each DOAC and the importance of improving patient adherence with DOAC therapy.
Bayer plc. commissioned and funded this article which contains promotional content. The company has reviewed the data to ensure factual accuracy in relation to Bayer products and compliance with industry guidelines. For Xarelto®▼ (rivaroxaban) prescribing information and adverse event reporting details please click here.
Document number: PP-M_RIV-GB-0030
Date of preparation: April 2021